Xenetic Biosciences (XBIO) Stock: Buy, Sell, or Hold?
XBIO - Xenetic Biosciences, Inc.
$1.72
-0.21 (-10.88%)
▼
5d:
-13.57%
30d:
-30.36%
90d:
-31.2%
WAIT
LOW Confidence
Analysis Updated: Oct 23, 2026 12:00 AM ET
Earnings: Nov 11, 2026
17d
Get Alerted When XBIO Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: XBIO is down 13.6% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: XBIO is down 13.6% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: XBIO is currently trading at $1.72, which is considered oversold relative to its 30-day fair value range of $1.79 to $2.94.
Technical Outlook: Technically, XBIO is in a downtrend. The price is currently testing key support at $1.72. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 10.9% recently.
Market Sentiment: XBIO scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $40.00 (+2225.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, XBIO is in a downtrend. The price is currently testing key support at $1.72. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 10.9% recently.
Market Sentiment: XBIO scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $40.00 (+2225.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$1.79 -
$2.94
Company Quality Score
40/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
52.6%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-10.9%)
- BULLISH: Trading 2225.6% below Wall St target ($40.00)
- WARNING: Composite score 40/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$1.79 -
$2.94
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$1.72
Resistance Level
$2.27
Current Trend
Downtrend
Technical data as of
Oct 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-5.06
Wall Street Target
$40.00
(+2225.6%)
Revenue Growth (YoY)
12.0%
Profit Margin
-75.9%
Share & Embed Analysis
Last updated: October 23, 2026 8:09 PM ET
Data refreshes hourly during market hours. Next update: 9:09 PM
Data refreshes hourly during market hours. Next update: 9:09 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is XBIO showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ARGX
argenx NV ADR |
STRONG BUY
25 analysts |
$1153 | 52 HOLD |
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
24 analysts |
$139 | 49 HOLD |
|
DNTH
Dianthus Therapeutics In… |
STRONG BUY
17 analysts |
$141 | 52 HOLD |
|
IRD
Opus Genetics, Inc. |
STRONG BUY
18 analysts |
$13 | 47 HOLD |
|
BNTX
BioNTech SE |
BUY
21 analysts |
$117 | 53 HOLD |
